Rallybio Corporation (RLYB) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rallybio (RLYB) has completed a Phase 1 trial titled “Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants.” The study tests repeat dosing of RLYB116, a complement inhibitor, to build a safety and dosing base for later trials in blood and autoimmune diseases.
The treatment is RLYB116 for Injection, a small engineered protein that blocks a part of the immune system called C5 to reduce harmful inflammation. It is given weekly and is designed to stay in the blood longer, with the goal of supporting chronic use in future patient studies.
This was an interventional Phase 1 study in healthy volunteers, with participants randomly assigned to different dose groups or placebo. Both participants and investigators were blinded, so neither knew who received active drug or placebo, and the main goal was to test safety while also tracking how the drug moves and acts in the body.
According to the registry, the trial was first submitted on January 22, 2025, marking the formal start of public tracking. The last update was filed on February 24, 2026, and the overall status is now listed as completed, which signals that dosing and follow‑up have finished and data analysis is likely underway.
For investors, a completed Phase 1 study in a novel complement inhibitor is a key de‑risking step for Rallybio, especially as complement drugs from players like Alexion and others have shown strong commercial potential. Positive safety data could support a pivot into larger patient trials and may lift sentiment toward RLYB if the market sees a credible path into high‑value autoimmune and hematology indications.
The Phase 1 study of RLYB116 is now completed and has been recently updated, with further details available on the ClinicalTrials portal.
To learn more about RLYB’s potential, visit the Rallybio Corporation drug pipeline page.